Altogether, these study results show that the participation of BCMA in SLE pathogenesis is more critical than previously thought, and we consider BCMA particularly relevant for current clinical trials targeting the cytokines BAFF/APRIL. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.